National and Kapodistrian University of Athens
Η επίδραση της σύγχρονης αντιρετροϊκής αγωγής στους δείκτες καρδιαγγειακής νοσηρότητας και ανοσολογικής διέγερσης σε ασθενείς με HIV λοίμωξη που δεν έχουν λάβει αντιρετροϊκή θεραπεία στο παρελθόν
Abstract
dc:descriptionHuman immunodeficiency virus (HIV) infection represents a major cardiovascular risk factor and the cardiovascular disease (CVD) burden among ageing people living with HIV (PLWH) constitutes a leading cause of morbidity and mortality. Therefore, it is necessary to evaluate and properly stratify the cardiovascular risk assessment in PLWH with appropriate screening tools. This approach will optimize the stratification of patients who are at higher risk for CVD and will benefit most from prevention measures and timely management. Endothelial glycocalyx may represent such a potential assessment tool as its derangement has been associated with CVD. However, studies on endothelial integrity among PLWH, are lacking. We conducted a prospective cohort study among treatment-naïve PLWH who received tenofovir alafenamide fumarate / emtricitabine (TAF/FTC), combined with either an integrase strand transfer inhibitor (INSTI, dolutegravir, raltegravir or elvitegravir/cobicistat), or a protease inhibitor (PI, darunavir/cobicistat). We assessed endothelial glycocalyx at baseline, at 24 (±4) and at 48 (±4) weeks, by measuring the Perfused Boundary Region (PBR), the area that is permeable by erythrocytes, and thus it is inversely proportional to EG thickness, in sublingual microvessels. In total, 66 consecutive PLWH [60 (90.9%) males] with a median age (interquartile range, IQR) of 37 (12) years, were enrolled. In total, 40 (60.6%) received an INSTI-based regimen. The mean (standard deviation, SD) PBR decreased significantly from 2.17 (0.29) μm at baseline to 2.04 (0.26) μm (p = 0.019), and then to 1.93 (0.3) μm (p <0.0001) at 24 (±4) and 48 (±4) weeks, respectively. PBR did not differ among treatment groups. However, PLWH on INSTIs had a sytatistically significant PBR reduction at 48 (±4) weeks. Smokers and PLWH with low viremia level experienced the greatest PBR reduction. This study is the first reporting the benefit of antiretroviral treatment on glycocalyx improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fragkou, Paraskevi
- Φράγκου, Παρασκευή
Subjects
dc:subject × 16- Ιός της ανοσοανεπάρκειας του ανθρώπου
- Ενδοθηλιακός γλυκοκάλυκας
- Συνδυασμένη αντιρετροϊκή αγωγή
- Ενεργοποίηση ανοσολογικού συστήματος
- Δείκτες καρδιαγγειακής νόσου
- Human immunodeficiency virus (HIV)
- Endothelial glycocalyx
- Antiretroviral therapy
- Immune response
- Cardiovascular risk markers
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- Cardiology and Cardiovascular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54464